Kymera Therapeutics, Inc. · NASDAQ:KYMR
Kymera Therapeutics — J.P. Morgan Healthcare Conference 2025
27 slides from Kymera Therapeutics's conference presentation, January 2025
Slide 1: J.P. Morgan Healthcare Conference
January 2025 J.P. Morgan Healthcare Conference Nello Mainolfi, Ph.D., Founder, President and CEO
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. These statements include, but are not limited to, implied and express statements about our strategy, business
Slide 3: Revolutionizing Immunology: Oral Drugs with Biologics-Like Efficacy
Revolutionizing Immunology: Oral Drugs with Biologics-Like Efficacy Science-driven clinical stage organization with industry-leading oral immunology pipeline • Targeted Protein Degradation (TPD) leader • Best-in-industry capabilities in hit finding and optimization of oral degraders • Unique target
Slide 4: Clear Vision and History of Strong Execution
Clear Vision and History of Strong Execution VISION EXECUTION IMPACT • Reinventing the treatment of • Delivered 5 new • Dosed over 300 healthy human disease as a fully investigational degrader volunteers/patients to date integrated commercial global drugs into the clinic since across clinical pipeli
Slide 5: Targeted Protein Degradation: New Modality Expanding the Range of Treatable Disease
Targeted Protein Degradation: New Modality Expanding the Range of Treatable Disease Targeted Protein Degradation Existing modalities have limitations that restrict their application leaving millions of patients without adequate treatment options. Traditional RNAi Small Molecule Yet 80% of disease-ca
Slide 6: Immunology: A Large, Underserved Market
Immunology: A Large, Underserved Market Oral Degraders with ~160M Total Patients Across Key Immunologic Diseases1 Biologics-Like Profiles Advanced Therapies: ~5M (3%) Can Disrupt the Immunology Market >$100B >$500B? • ∼5M patients (3% of Non-Advanced total diagnosed) are on Therapies: • ∼ 97% of the
Slide 7: Small Molecule Oral Degraders Can Transform Immunology
Small Molecule Oral Degraders Can Transform Immunology Potentially Superior Profile to Injectable Biologics and Traditional Small Molecule Inhibitors Biologics have several limitations: Orals preferred by most patients: • Expensive, challenging to prescribe/reimburse • In multiple surveys1, 75% of p
Slide 8: Unique Target Selection Strategy Drives Best-In-Class Pipeline
Unique Target Selection Strategy Drives Best-In-Class Pipeline Undrugged or Clear path to inadequately STAT6 early clinical drugged differentiation targets Strong TYK2 IRAK4 Large clinical/ genetic/clinical commercial validation opportunities FOCUS ON FIRST- AND BEST-IN-CLASS OPPORTUNITIES 8
Slide 9: Industry Leader at Developing Oral Degrader Drugs
Industry Leader at Developing Oral Degrader Drugs Hit Finding, Structural Biology and Chemistry Comprehensive Proprietary Technologies to Best-in-Industry Structural Biology Capabilities Identify Novel Ligands to Undrugged Proteins Across all Programs Virtual Fragment- Cysteine Example: Cereblon-(KT
Slide 10: Building the Best-In-Industry Oral Immunology Pipeline
Building the Best-In-Industry Oral Immunology Pipeline Potential IND-Enabling Phase 1 Phase 2 OPPORTUNITY Indications Kymera Wholly-Owned AD, Asthma, COPD, Dupilumab-like activity STAT6 PN, CRSwNP, EoE, BP, KT-621 in a pill others TYK2-LOF profile to deliver Psoriasis, IBD, PsA, TYK2 Lupus, others K
Slide 11: Oral Degraders in Immunology With Significant Market Potential
Oral Degraders in Immunology With Significant Market Potential First-In-Industry: Orals with Biologics-Like Profiles Could Change the Commercial Landscape STAT6 TYK2 IRAK4 TRANSCRIPTION FACTOR SCAFFOLDING KINASE SCAFFOLDING KINASE Key Indications: AD, Asthma, COPD, Key Indications: PsO, PsA, SLE, UC
Slide 12: TYK2: Replicating Human Genetics to Deliver Biologics-Like Efficacy with an Oral Pill
TYK2: Replicating Human Genetics to Deliver Biologics (i.e., IL-23)- Like Efficacy with an Oral Pill Cytokine Pathway IL-23 Type I IFN IL-12 IL-10 TYK2 SCAFFOLDING Only a degrader WT TYK2 ++++ ++++ ++++ ++++ KINASE can eliminate all Type I IL-23 IL-12 scaffolding and Complete deficiency TYK2 -/- + +
Slide 13: IRAK4: Combined Activity of Upstream Biologics in an Oral Pill
IRAK4: Combined Activity of Upstream Biologics (IL-1/18/33/36) in an Oral Pill LPS + IL-1 → IL-6 IRAK4 Inhibitor Only a degrader %IL-6 (Control) SCAFFOLDING KINASE can fully block TLRs IL-1R IL1/TLR signaling Degrader MyD88 IRAK4 Log[Compound] (nM) KT-474 IRAK1/2 TRAF6 KT-474 Ph1 Study: Robust Degr
Slide 14: KT-621: First-In-Industry STAT6 Degrader
KT-621: First-In-Industry STAT6 Degrader A Paradigm Shift in Immunology 14
Slide 15: STAT6 Degrader: Dupilumab-Like Activity in a Pill
STAT6 Degrader: Dupilumab-Like Activity in a Pill Best-in-Pathway Mechanism STAT6 TRANSCRIPTION FACTOR • Dupilumab (IL-4Rα mAb) approved for multiple indications IL-4/13 Pathway • Gain of function variants cause Type I IL-4 Type II IL-4 Clinical and genetic severe allergic diseases Receptor Receptor
Slide 16: KT-621: A Highly Selective and Potent Oral STAT6 Degrader
KT-621: A Highly Selective and Potent Oral STAT6 Degrader Only STAT6 is Degraded in Human Cells Even at High Full STAT6 Degradation in All Relevant Human Cell Concentrations (100 x DC90) Types at Picomolar Concentrations (DC50) T cell = 36 pM STAT6 STAT6 Monocyte = 60 pM Other STATS B Cell = 86 pM 1
Slide 17: KT-621: Potency Similar or Superior to Dupilumab in Human Cells
KT-621: An Oral STAT6 Degrader with Potency Similar or Superior to Dupilumab in Human Cells KT-621 Fully Blocks IL-4/13 Pathway in Human Th2 Functional Assays with IC50’s Lower than Dupilumab IL-4 Induced Periostin Release in Human IL-13 Induced TAC1 Expression in iPSC Bronchial Smooth Muscle Cell D
Slide 18: KT-621: Potency Similar or Superior to Dupilumab in In Vivo Preclinical Models
KT-621: An Oral STAT6 Degrader with Potency Similar or Superior to Dupilumab in In Vivo Preclinical Models KT-621 Blocks Th2 Inflammation In Vivo Equally/Better than a Saturating Dose of Dupilumab in Mouse HDM Asthma Model TARC (CCL17) Reduction in Lungs Reduction in Lung Goblet Cell Metaplasia 104
Slide 19: KT-621 Compelling Preclinical PK/PD and Safety Holds Promise
KT-621 Compelling Preclinical PK/PD and Safety Holds Promise for Positive Human Translation KT-621 Potently Degrades STAT6 to Depletion with Low Oral Doses Across Multiple Preclinical Species and in Multiple Tissues STAT6 Degradation in Dog Blood Post 7 Days STAT6 Degradation in NHP Tissues Post 14
Slide 20: Kymera's Goal is to Build a STAT6 Franchise That Will Serve ALL Patients
Kymera’s Goal is to Build a STAT6 Franchise That Will Serve ALL Patients with Th2 Inflammation >130 million diagnosed mild and moderate/severe patients across 46.5% the seven major markets1 Mild 1% Treated with Systemic Advanced Therapy 52.5% (>$10B market1) Moderate/Severe Kymera is the leader in t
Slide 21: Opportunity to Transform Treatment Paradigm in Th2 Inflammation
Opportunity to Transform Treatment Paradigm in Th2 Inflammation Examples: Atopic Dermatitis and Asthma Atopic Non-Rx. Management Topicals Therapy Systemic Advanced Therapy (Emollients, salt baths, (Corticosteroids, Calcineurin, Dermatitis1 trigger avoidance) PDE4, JAK inhibitors) (Biologic: IL-4/13,
Slide 22: KT-621: First STAT6 Agent to Enter Clinical Evaluation
KT-621: First STAT6 Agent to Enter Clinical Evaluation Phase 1 Trial: Double-blind, Placebo-controlled SAD and MAD in Healthy Volunteers • Safety & tolerability of 2Q 2025 Part A Primary escalating single and Single Ascending Dose multiple doses of KT-621 Phase 1 Healthy (SAD) Volunteer Data Seconda
Slide 23: KT-621 on Track for Full Development Across at Least Eight Dupilumab Established Indications
KT-621 on Track for Full Development Across at Least Eight Dupilumab Established Indications Initial Parallel Development in Moderate/Severe Atopic Dermatitis (AD) and Asthma is Expected to Enable Accelerated Late Parallel Development Across All Other Dermatology/GI and Respiratory indications DERMA
Slide 24: Pipeline with Clear Line of Sight to Large Value Creation
Pipeline with Clear Line of Sight to Large Value Creation Potential Upcoming 2025 1H 2026 Indications Milestones Immunology – Oral QD Small Molecule Degraders AD, Asthma, Ph1 HV Ph1b AD Ph2b AD Ph1 HV Data: 2Q25 STAT6 COPD, PN, Ph1b AD Data: 4Q25 CRSwNP, EoE, Safety, STAT6 Biomarkers in KT-621 degra
Slide 25: Thank You
Thank You NASDAQ: KYMR For additional information contact: www.kymeratx.com investors@kymeratx.com @KymeraTX media@kymeratx.com inquiries@kymeratx.com KYMERA THERAPEUTICS 500 North Beacon Street, 4th Floor Watertown, MA 02472
Slide 26: Abbreviations
Abbreviations Ab Antibody FIH First-in-Human JAK Janus Kinase AD Atopic Dermatitis GLP Good Laboratory Practice JP Japan ASMS Affinity Selection Mass Spectrometry GOF Gain of Function KO Knockout AN Count Abscess and Inflammatory Nodule Count GPP Generalized Pustular Psoriasis LABA Long-Acting Beta
Slide 27: Abbreviations
Abbreviations PsA Psoriatic Arthritis UC Ulcerative Colitis PsO Psoriasis US United States QD Once a day WW Worldwide R&D Research and Development RA Rheumatoid Arthritis ROW Rest of World RP Recurrent Pericarditis SAD Single Ascending Dose study SLE Systemic Lupus Erythematosus SMI Small Molecule I
Kymera Therapeutics — J.P. Morgan Healthcare Conference 2025 on 6ix